中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

高频不可逆电穿孔消融猪胰腺组织的效果观察

幸嵘 杜霁儒 翁原驰 王峰 刘超

引用本文:
Citation:

高频不可逆电穿孔消融猪胰腺组织的效果观察

DOI: 10.12449/JCH240523
基金项目: 

山东省自然科学基金面上项目 (ZR2023MH111)

医学伦理声明本实验中的所有操作均遵守动物福利法规,且已通过上海甲干生物科技有限公司伦理委员会批准,批号:JGLL-20210316002。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:幸嵘负责实验设计和操作,资料分析,撰写论文;杜霁儒负责资料分析,撰写论文;翁原驰负责动物实验操作;王峰参与实验设计及修改论文;刘超负责拟定写作思路,指导撰写文章并最后定稿。幸嵘、杜霁儒对本文贡献等同,同为第一作者。
详细信息
    通信作者:

    刘超, liuchao2311@126.com (ORCID: 0009-0002-9203-5800)

Effect of high-frequency irreversible electroporation in the ablation of porcine pancreatic tissue

Research funding: 

Shandong Provincial Natural Science Foundation Project (ZR2023MH111)

More Information
  • 摘要:   目的  探索高频不可逆电穿孔(H-FIRE)消融猪胰腺组织的效果。  方法  采用开腹手术,借助针式电极对12只猪释放电脉冲,按照场强数值小、中、大设置三组参数(1 000 V/cm、1 500 V/cm、2 500 V/cm)进行消融。通过比较各组术后恢复情况、消融面积、组织病理学表现等数据验证H-FIRE消融猪胰腺组织的安全性、有效性。计量资料两组间比较使用配对t检验。  结果  所有实验猪均存活,且获得明确的消融效果,各组组织病理学均提示,消融有效彻底,消融区与正常组织区分界明显,小场强组、中场强组、大场强组平均消融面积分别为(30.96±3.73)mm2、(51.93±25.26)mm2、(108.90±55.23)mm2,大、中场强组消融面积均显著大于小场强组(P值均<0.05),中场强组与大场强组消融面积差异无统计学意义(P>0.05)。  结论  在特定的消融参数下,对猪胰腺进行H-FIRE消融安全、有效。

     

  • 图  1  实验猪行H-FIRE消融术中情况

    注: a,胰腺行H-FIRE消融过程中;b,消融后撤除电极针(箭头所示为消融部位)。

    Figure  1.  Intraoperative situation during the H-FIRE ablation procedure in the experimental pigs

    图  2  实验猪胰腺行H-FIRE消融术后7天病理表现

    注: a~c(小、中、大场强),实线勾画出区域即消融区,其中心表现为片状坏死,周围胰腺组织变性,纤维组织增生,炎细胞浸润(HE染色, ×0.86, ×0.45,×0.31);d~f(小、中、大场强),显示损伤灶内胰腺组织变性坏死及局灶出血改变(HE染色,×20)。

    Figure  2.  Pathological findings at 7th day after H-FIRE ablation

    图  3  各组参数的消融区域面积比较

    Figure  3.  Comparison of the ablation area of each group

    图  4  实验猪胰腺行H-FIRE消融术后7天MRI表现

    注: a,T1W横断面显示主胰管扩张,胰管近端胰头消融区域斑片状低信号,边界清晰;b,T2W横断面显示消融区为不均匀高信号,边界欠清;c,增强扫描显示消融区域内无强化,边界较清晰。箭头所示实线勾画的区域即消融灶。

    Figure  4.  MRI findings at 7th day after H-FIRE ablation

    表  1  实验室检查结果

    Table  1.   Laboratory test results

    指标 术前(n=12) 术后第7天(n=12) t P
    红细胞计数(×1012/L) 6.86±1.09 6.81±1.16 0.11 0.915
    血红蛋白(g/L) 121.00±5.73 119.00±9.31 0.59 0.568
    白细胞计数(×109/L) 15.22±1.40 20.50±2.02 10.63 <0.001
    血小板计数(×109/L) 388.00±109.01 438.67±84.06 1.31 0.216
    血清淀粉酶(U/L) 3 170.67±1 235.67 2 988.00±1 403.83 0.41 0.688
    下载: 导出CSV
  • [1] TORRE LA, SIEGEL RL, WARD EM, et al. Global cancer incidence and mortality rates and trends: An update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25( 1): 16- 27. DOI: 10.1158/1055-9965.EPI-15-0578.
    [2] KWON W, THOMAS A, KLUGER MD. Irreversible electroporation of locally advanced pancreatic cancer[J]. Semin Oncol, 2021, 48( 1): 84- 94. DOI: 10.1053/j.seminoncol.2021.02.004.
    [3] ZHANG ZH, HE SL, WANG P, et al. The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: A systematic review and meta-analysis[J]. J Gastrointest Oncol, 2022, 13( 4): 1967- 1980. DOI: 10.21037/jgo-22-624.
    [4] SPRINGFELD C, JÄGER D, BÜCHLER MW, et al. Chemotherapy for pancreatic cancer[J]. Presse Med, 2019, 48( 3 Pt 2): e159- e174. DOI: 10.1016/j.lpm.2019.02.025.
    [5] GEBOERS B, SCHEFFER HJ, GRAYBILL PM, et al. High-voltage electrical pulses in oncology: Irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy[J]. Radiology, 2020, 295( 2): 254- 272. DOI: 10.1148/radiol.2020192190.
    [6] LIU CP, YE P, ZHANG MY. Research progress in irreversible electroporation ablation for tumors[J]. J Interv Radiol, 2023, 32( 5): 498- 502. DOI: 10.3969/j.issn.1008-794X.2023.05.018.

    刘春苹, 叶萍, 张明悦. 不可逆电穿孔对肿瘤消融的研究进展[J]. 介入放射学杂志, 2023, 32( 5): 498- 502. DOI: 10.3969/j.issn.1008-794X.2023.05.018.
    [7] GARCIA PA, KOS B, ROSSMEISL JH Jr, et al. Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma[J]. Med Phys, 2017, 44( 9): 4968- 4980. DOI: 10.1002/mp.12401.
    [8] LATOUCHE EL, SANO MB, LORENZO MF, et al. Irreversible electroporation for the ablation of pancreatic malignancies: A patient-specific methodology[J]. J Surg Oncol, 2017, 115( 6): 711- 717. DOI: 10.1002/jso.24566.
    [9] QASRAWI R, SILVE L, BURDÍO F, et al. Anatomically realistic simulations of liver ablation by irreversible electroporation: Impact of blood vessels on ablation volumes and undertreatment[J]. Technol Cancer Res Treat, 2017, 16( 6): 783- 792. DOI: 10.1177/1533034616687477.
    [10] MARTIN RC, SCHWARTZ E, ADAMS J, et al. Intra-operative anesthesia management in patients undergoing surgical irreversible electroporation of the pancreas, liver, kidney, and retroperitoneal tumors[J]. Anesth Pain Med, 2015, 5( 3): e22786. DOI: 10.5812/aapm.22786.
    [11] MEROLA G, FUSCO R, DI BERNARDO E, et al. Design and characterization of a minimally invasive bipolar electrode for electroporation[J]. Biology(Basel), 2020, 9( 9): 303. DOI: 10.3390/biology9090303.
    [12] LEE EW, SHAHROUKI P, PETERSON S, et al. Safety of irreversible electroporation ablation of the pancreas[J]. Pancreas, 2021, 50( 9): 1281- 1286. DOI: 10.1097/MPA.0000000000001916.
    [13] AGNASS P, van VELDHUISEN E, VOGEL JA, et al. Thermodynamic profiling during irreversible electroporation in porcine liver and pancreas: A case study series[J]. J Clin Transl Res, 2020, 5( 3): 109- 132.
    [14] SOROKIN I, CANVASSER N, JOHNSON B, et al. Irreversible electroporation for renal ablation does not cause significant injury to adjacent ureter or bowel in a porcine model[J]. J Endourol, 2021, 35( 6): 873- 877. DOI: 10.1089/end.2020.0856.
    [15] MA XY, XIAO YY, ZHANG X, et al. Comparison of irreversible electroporation with cryotherapyablation in porcine liver tissue[J]. Chin J Interv Imag Ther, 2015, 12( 5): 267- 270. DOI: 10.13929/j.1672-8475.2015.05.004.

    马旭阳, 肖越勇, 张欣, 等. 不可逆电穿孔与冷冻治疗消融猪肝脏组织对比分析[J]. 中国介入影像与治疗学, 2015, 12( 5): 267- 270. DOI: 10.13929/j.1672-8475.2015.05.004.
    [16] MIZRAHI JD, SURANA R, VALLE JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395( 10242): 2008- 2020. DOI: 10.1016/S0140-6736(20)30974-0.
    [17] GUGENHEIM J, CROVETTO A, PETRUCCIANI N. Neoadjuvant therapy for pancreatic cancer[J]. Updates Surg, 2022, 74( 1): 35- 42. DOI: 10.1007/s13304-021-01186-1.
    [18] ZHANG BL, ZHOU FY, HONG JZ, et al. The role of FOLFIRINOX in metastatic pancreatic cancer: A meta-analysis[J]. World J Surg Oncol, 2021, 19( 1): 182. DOI: 10.1186/s12957-021-02291-6.
    [19] PASSARDI A, RAPPOSELLI IG, SCARPI E, et al. Multimodal treatment with GEMOX plus helical tomotherapy in unresectable locally advanced pancreatic cancer: A pooled analysis of two phase 2 studies[J]. Biomolecules, 2021, 11( 8): 1200. DOI: 10.3390/biom11081200.
    [20] General Office of National Health Commission. Standard for diagnosis and treatment of pancreatic cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 5): 1006- 1030. DOI: 10.3969/j.issn.1001-5256.2022.05.007.

    国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 5): 1006- 1030. DOI: 10.3969/j.issn.1001-5256.2022.05.007.
    [21] TASU JP, TOUGERON D, ROLS MP. Irreversible electroporation and electrochemotherapy in oncology: State of the art[J]. Diagn Interv Imaging, 2022, 103( 11): 499- 509. DOI: 10.1016/j.diii.2022.09.009.
    [22] LIANG B, NIU LZ, ZENG JY, et al. Irreversible electroporation ablation of the hepatic region close to the gallbladder: Pathological observation in experimental rabbits[J]. J Interv Radiol, 2014, 23( 4): 320- 324. DOI: 10.3969/j.issn.1008-794X.2014.04.012.

    梁冰, 牛立志, 曾健滢, 等. 不可逆电穿孔消融兔胆囊侧肝脏病理学观察[J]. 介入放射学杂志, 2014, 23( 4): 320- 324. DOI: 10.3969/j.issn.1008-794X.2014.04.012.
    [23] NIU LZ, ZENG JY, ZHANG YS, et al. Irreversible electroporation ablation therapy for pancreatic adenocarcinoma: Observation of its safety and short-term effect[J]. J Interv Radiol, 2016, 25( 3): 225- 230.

    牛立志, 曾健滢, 张怡湜, 等. 不可逆电穿孔消融治疗胰腺癌的安全性及近期疗效观察[J]. 介入放射学杂志, 2016, 25( 3): 225- 230.
    [24] MEIJERINK MR, RUARUS AH, VROOMEN LGPH, et al. Irreversible electroporation to treat unresectable colorectal liver metastases(COLDFIRE-2): A phase II, two-center, single-arm clinical trial[J]. Radiology, 2021, 299( 2): 470- 480. DOI: 10.1148/radiol.2021203089.
    [25] RUARUS AH, VROOMEN LGPH, GEBOERS B, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer(PANFIRE-2): A multicenter, prospective, single-arm, phase II study[J]. Radiology, 2020, 294( 1): 212- 220. DOI: 10.1148/radiol.2019191109.
    [26] WAH TM, LENTON J, SMITH J, et al. Irreversible electroporation(IRE) in renal cell carcinoma(RCC): A mid-term clinical experience[J]. Eur Radiol, 2021, 31( 10): 7491- 7499. DOI: 10.1007/s00330-021-07846-5.
    [27] WANG HF, XUE W, YAN WG, et al. Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: A nonrandomized controlled trial[J]. JAMA Surg, 2022, 157( 8): 693- 700. DOI: 10.1001/jamasurg.2022.2230.
    [28] Chinese Society of Interventional and Minimally Invasive Therapy, China Medicine Education Association. Expert consensus on image-guided irreversible electroporation ablation for pancreatic cancer(2018)[J]. J Clin Hepatol, 2019, 35( 2): 299- 302. DOI: 10.3969/j.issn.1001-5256.2019.02.011.

    中国医药教育协会介入微创治疗专业委员会. 影像学引导胰腺癌不可逆电穿孔消融治疗专家共识2018版[J]. 临床肝胆病杂志, 2019, 35( 2): 299- 302. DOI: 10.3969/j.issn.1001-5256.2019.02.011.
    [29] RASHID MF, HECHT EM, STEINMAN JA, et al. Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist[J]. Abdom Radiol(NY), 2018, 43( 2): 457- 466. DOI: 10.1007/s00261-017-1349-3.
  • 加载中
图(4) / 表(1)
计量
  • 文章访问数:  324
  • HTML全文浏览量:  276
  • PDF下载量:  37
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-08-30
  • 录用日期:  2023-10-27
  • 出版日期:  2024-05-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回